Cardiotoxicity and oncological treatments.
暂无分享,去创建一个
C. Thomssen | D. Vordermark | A. Schlitt | K. Jordan | T. Langer | J. Schwamborn | Christoph Thomssen | Axel Schlitt | Karin Jordan | D. Vordermark | Jürgen Schwamborn | Thorsten Langer
[1] A. Bedewy,et al. XPD gene polymorphisms and the effects of induction chemotherapy in cytogenetically normal de novo acute myeloid leukemia patients , 2014, Hematology.
[2] J. Esteve,et al. Reply: Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies. , 2013, Journal of the American College of Cardiology.
[3] P. Mazzanti,et al. State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: a literature review. , 2013, Critical reviews in oncology/hematology.
[4] B. Khandheria,et al. Cardioncology: state of the heart. , 2013, International journal of cardiology.
[5] G. Armstrong,et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. , 2013, JAMA.
[6] J. Esteve,et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of , 2013, Journal of the American College of Cardiology.
[7] P. Hall,et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. , 2013, The New England journal of medicine.
[8] C. Geyer,et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] E. Yeh,et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity , 2012, Nature Medicine.
[10] C. Koning,et al. High risk of symptomatic cardiac events in childhood cancer survivors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] L. Moja,et al. Trastuzumab containing regimens for early breast cancer. , 2012, The Cochrane database of systematic reviews.
[12] G. Ertl,et al. [The German National Disease Management Guideline "Chronic Heart Failure"]. , 2012, Deutsche medizinische Wochenschrift.
[13] Marc Buyse,et al. Adjuvant trastuzumab in HER2-positive breast cancer. , 2011, The New England journal of medicine.
[14] H. Caron,et al. The use of liposomal anthracycline analogues for childhood malignancies: A systematic review. , 2011, European journal of cancer.
[15] D. Cunningham,et al. Cardiotoxicity in patients treated with bevacizumab is potentially reversible. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] G. Mantovani,et al. Long-term protective effects of the angiotensin receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress and myocardial dysfunction. , 2011, Experimental and therapeutic medicine.
[17] M. Beer,et al. Cardiac magnetic resonance imaging findings in 20-year survivors of mediastinal radiotherapy for Hodgkin's disease. , 2011, International Journal of Radiation Oncology, Biology, Physics.
[18] R. Pötter,et al. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for hodgkin disease in children and adolescents: Report from the longitudinal GPOH follow‐up project of the German–Austrian DAL‐HD studies , 2010, Pediatric blood & cancer.
[19] H. Caron,et al. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. , 2010, The Cochrane database of systematic reviews.
[20] F. Roila,et al. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] Peter A Fasching,et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] L. A. Bonet,et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.
[23] R. Kreienberg,et al. First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] E. Yeh,et al. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. , 2009, Journal of the American College of Cardiology.
[25] E. D. de Vries,et al. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. , 2009, The Lancet. Oncology.
[26] R. Hoffmann,et al. Manual zur Indikation und Durchführung der Echokardiographie , 2009 .
[27] F. Holmes,et al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] C. Bokemeyer,et al. Kardiotoxizitäten bei Chemo- und Radiotherapie , 2009, Der Onkologe.
[29] M. Kalmanti,et al. Troponins and natriuretic peptides in the monitoring of anthracycline cardiotoxicity , 2008, Pediatric blood & cancer.
[30] L. Wojnowski,et al. [Chemotherapeutics-induced heart failure]. , 2007, Medizinische Klinik.
[31] W. Dahut,et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[32] C. Angermann,et al. 3-D reconstruction of anterior mantle-field techniques in Hodgkin's disease survivors: doses to cardiac structures , 2006, Radiation oncology.
[33] S. Bielack,et al. Prospective longitudinal evaluation of doxorubicin‐induced cardiomyopathy in sarcoma patients: A report of the late effects surveillance system (LESS) , 2006, Pediatric blood & cancer.
[34] J. Goodwin,et al. Cardiac morbidity of adjuvant radiotherapy for breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] A. Hoes,et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.
[36] James S Goodwin,et al. Risk of cardiac death after adjuvant radiotherapy for breast cancer. , 2005, Journal of the National Cancer Institute.
[37] S. Lipsitz,et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] C. Hall. Essential biochemistry and physiology of (NT‐pro)BNP , 2004, European journal of heart failure.
[39] Giovanni Martinelli,et al. Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. , 2003, Clinical chemistry.
[40] M. Sigmund,et al. Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[41] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[42] L. Burke,et al. Symptomatic Cardiotoxicity Associated with 5‐Fluorouracil , 1997, Pharmacotherapy.
[43] J. Krischer,et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] G. Hortobagyi,et al. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] K. Jungius,et al. [5-fluorouracil: cause of a fatal myocardial infarction in combined radiochemotherapy?]. , 1996, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].
[46] D Tripathy,et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] F. Bu'Lock,et al. Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms, and pathophysiology. , 1995, British heart journal.
[48] S. Sallan,et al. Cardiovascular abnormalities in long-term survivors of childhood malignancy. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] R. Kloner,et al. 5‐Fluorouracil Cardiotoxicity: Left Ventricular Dysfunction and Effect of Coronary Vasodilators , 1987, The American journal of the medical sciences.
[50] A. Burger,et al. 5-Fluorouracil-induced coronary vasospasm. , 1987, American heart journal.
[51] P. Seeburg,et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. , 1985, Science.
[52] D. V. Von Hoff,et al. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. , 1977, The American journal of medicine.
[53] M. Zibelman,et al. Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer , 2013 .
[54] M. Dowsett,et al. years versus 1 year of adjuvant trastuzumab for HER 2-positive breast cancer ( HERA ) : an open-label , randomised controlled trial , 2013 .
[55] L. A. Bonet,et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.
[56] P. Russo. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma , 2009 .
[57] Risk of proteinuria, hypertension with bevacizumab , 2007 .
[58] H. Dickinson,et al. Cardioprotective interventions for cancer patients receiving anthracyclines. , 2005, The Cochrane database of systematic reviews.
[59] P. Vici,et al. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review , 2003, Journal of Cancer Research and Clinical Oncology.
[60] Steven E Lipshultz,et al. Radiation-associated cardiovascular disease. , 2003, Critical reviews in oncology/hematology.
[61] G Noël,et al. [Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials]. , 2001, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.
[62] P. Kaufmann,et al. Cardiac risk after mediastinal irradiation for Hodgkin's disease. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[63] M. Christian,et al. A reassessment of cardiac toxicity associated with Taxol. , 1993, Journal of the National Cancer Institute. Monographs.